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Utility  of  a predictive  model  fo
level 1  medical  care
Utilidad  de  un  modelo  de  predicció
crónica  en  una  unidad  de  primer  n
To the Editor,
The 2014 Spanish agreement Document for the Detection and
Management of Chronic Kidney Disease (CKD) recommended
that, in people with risk factors for development of and pro-
gression of CKD, the doctor should take certain preventive
measure.1
Despite these recommendations, the prevalence of CKD
continues to rise. In Mexico, one of the Latin American
countries with the highest prevalence of CKD,2,3 there was an
increase from 394 to 986 (patient per million) ppm from 2003
to 2007.
To help primary care physicians to monitor groups at risk,
a model was constructed to predict probability of developing
CKD, depending on the different combinations of risk factors
that can be detected in a family medicine clinic.
DOI of original article:
http://dx.doi.org/10.1016/j.nefro.2015.10.010.
 Please cite this article as: Gallardo Vidal LS, Rodríguez Méndez AJ, B
Herrera  ME, et al. Utilidad de un modelo de predicción para la enferme
Nefrologia. 2016;36:196–198.hronic  kidney  disease  in
para  la  enfermedad  renal
el  de  atención
This was a case–control study of patients treated in a
primary care unit of the Instituto Mexicano del Seguro Social (Mex-
ican Social Security Institute), Querétaro, Mexico, in 2013. The
sample size was calculated using the formula for two  propor-
tion, with a signiﬁcance level of 95%, test power 80%, OR 2.2,
considering a 1:1 ratio of patients with CKD for unpaired data
(n = 100 for each group).
Deﬁnition  of  groups
Cases: patients diagnosed with CKD by the renal depart-urgos Ochoa M, Martínez Martínez ML, García Solís P, Villagrán
dad renal crónica en una unidad de primer nivel de atención.
urinary creatinine clearance, both sexes, and those older than
18 years.
Controls: patients without CKD, glomerular ﬁltration rate
≥61 mL/min measured by the Cockcroft–Gault formula on 2
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Table 1 – Multiple logistic regression model to explain
chronic kidney disease.
Chi-square P-value
151.04 0.000
Coefﬁcient Statistic Signiﬁcance
Constant −16.116
Urological
disease
2.561 12.509 0.000
HTN 2.185 20.931 0.000
Use of
nephrotoxic
drugs
2.811  22.790 0.000
Hyperuricaemia 1.908 10.318 0.001
HTN, systemic hypertension.
The statistical analysis included a Chi-square test and the calcula-
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that were found to be signiﬁcant risk factors, expressed as per-
centages. The formula 1/(1+e−y) was used for this calculation.
The risk factors that could be used, due to their strong
association, to create the model were urological diseases,
systemic hypertension (HTN), hyperuricaemia, and use of
nephrotoxic drugs. Nephrotoxic drugs had the strongest asso-
ciation (Table 1). According to this model, there is a 99.9%
probability of developing CKD if a patient has all 4 risk fac-
tors. If a patient has a urological disease and uses long-term
nephrotoxic drugs, the probability is 92.8% (Table 2).
Although the factors that lead to CDK1,4,5 are widely stud-
ied, the fact is that prevention of CKD onset and progression
has not been achieved.3 Therefore, studies that allow the con-
struction of practical predictive models adjusted to speciﬁc
populations are of great relevance.
ic ki
erten
 
 tion of the multiple logistic regression model, with a 95% conﬁdence
interval.
ifferent occasions and conﬁrmed by a 24 h urinary creatinine,
oth sexes, and those older than 18 years.
Exclusion criteria were pregnancy and other causes of pro-
einuria. Patients with incomplete histories were not included.
Cases were chosen using simple random sampling, and
ontrols were chosen by non-probability quota sampling. The
isk factors established by the Spanish agreement Document
or CKD susceptibility, onset, and progression were taken into
ccount for the analysis, and only those that reached statisti-
al signiﬁcance were included in the model. The variables of
ex and age were not included, because they were part of the
ormula used to estimate glomerular ﬁltration rate.
A Chi-square test was used to estimate the risk of odds
atio (OR). Logistic regression analysis was used to construct
he model, with a method of progressive inclusion of variables,
ncluding those that reached statistical signiﬁcance, with a
5% conﬁdence level.
A probability risk analysis was performed, based on the fre-
uency of CKD with different combinations of the variables
Table 2 – Calculation of the probability of developing chron
Probability Urological disease Systemic hyp
Percentage
99.9 Present Present
99.1 Present Present
98.9 Present Absent 
98.4 Absent Absent 
97.9 Present Present 
92.8 Present Absent 
89.9 Absent Present 
87.3 Present Present 
87.0 Absent Absent 
84.0 Present Absent 
78.2 Absent Present 
49.9 Absent Absent 
43.7 Present Absent 
34.8 Absent Present 
28.8 Absent Absent 
5.7 Absent Absent 
The statistical analysis included the calculation of the multiple logistic
developing chronic kidney disease using the formula 1/(1+e−y).In this discussion, we  cannot ignore the use of nephrotoxic
drug; the probability of developing CKD with this risk factor
alone is 49.9%; this is a preventable factor in any population. It
must be mentioned that this rate is high due to the use of non-
steroidal anti-inﬂammatory drugs (NSAIDs). This is similar to
what author authors have found.6,7
In this model, urological disease was considered a sig-
niﬁcant risk factor, with a probability of 43.7%. Prostatic
enlargement was the most common disease. In the Mexican
population, late detection of prostatic enlargement is com-
mon, often due to men’s fear of exposing their privacy during
the clinical examination. This can lead to complications such
as CKD.8,9
In Mexico, the leading reason for consultation in primary
care is HTN, and, according to the proposed model, there is
a 34.8% probability of developing CKD with this factor alone.
Likewise, the strict monitoring of uric acid levels and their
timely control must not be abandoned.10
In conclusion, the model that predicted the highest prob-
ability of developing CKD was that which included urological
diseases, HTN, hyperuricaemia, and the use of nephrotoxic
drugs.
dney disease.
sion Nephrotoxic drugs Hyperuricaemia
Yes Present
Yes Absent
Yes Present
Yes Present
No Present
Yes Absent
Yes Absent
No Absent
Yes Present
No Present
No Present
Yes Absent
No Absent
No Absent
No Present
No Absent
 regression model and, later, the estimation of the probability of
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Cloudy  peritoneal  dialysate  ef
syndrome
Eﬂuente  peritoneal  turbio  debido  a
al  injerto  renal
To the Editor,The presence of cloudy peritoneal ﬂuid (PF) in patients on
peritoneal dialysis (PD) usually occurs in the context of infec-
tious peritonitis. For this diagnosis, two of the following three
criteria must be met: (1) the presence of abdominal pain,
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ent due  to graft intolerance
n  síndrome  de  intolerancia
(2) cloudy ﬂuid with more  than 100 leukocytes/L and more
than 50% of them polymorphonucleocytes, and (3) positive
1lina-Vila P, Montomoli M, Pallardó-Mateu LM, Ávila-Bernabeu A.
rto renal. Nefrologia. 2016;36:198–199.
culture from PF. There are many  causes of cloudy PF due to a
high cell count. Inﬂammation of juxtaperitoneal organs (pan-
creatitis, cholecystitis, splenic infarct, appendicitis, etc.) can
increase the number of polymorphonuclear lymphocytes in
